US 8283342
Napadisylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the β2 adrenergic receptor
granted A61KA61K31/439A61K31/573
Quick answer
US patent 8283342 (Napadisylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the β2 adrenergic receptor) held by Almirall, S.A. expires Mon Oct 04 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Almirall, S.A.
- Grant date
- Tue Oct 09 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 04 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 4
- CPC classes
- A61K, A61K31/439, A61K31/573, A61K45/06, A61K9/0075